Recent market research data shows that the overall world revenue for pain therapeutics will be approximately $68 billion in 2013. With an aging population and increase in prevalence of cancer, diabetes, arthritis and other disorders, the need for pain medications will continue to rise. Hence, it would be interesting to get some insights into what is really happening in the R&D pipeline for pain, as this will drive revenues going forward. Cambridge Healthtech Institute’s seventh annual conference on PAIN: Novel Drug Targets and Screening Tools brings together leading experts, from industry, academia and government/regulatory agencies, to discuss the latest developments and trends in pain research. This year the conference will continue its focus on innovative drug targets including ion channels and GPCRs, while bringing attention to epigenetic and genetic modulators of pain. The increasing role of biologics will be discussed, as well as, novel screening technologies and animal models that are helping validate some of these new targets and inhibitors.
Who should attend: This conference is largely designed around topics that are relevant to chemists and biologists in early discovery, who are designing molecules and screening compounds for targeting pain. Scientists involved in in vitro and in vivo screening, target validation, hit to lead studies, and biomarker discovery will find topics of interest. Scientists and clinicians from both industry and academia who are involved in translational research will likely benefit from learning about the new tools that are being utilized in the early stages of the drug development pipeline. Technology and service providers, CROs will also enjoy the active networking and collaborating opportunities.
Topics will include, but are not limited to:
- New Drug Targets for Pain: Ion Channels, GPCRs, PPARs, NGF antagonists
- Exploring Allosteric Inhibitors and Immunomodulators
- Genetic and Epigenetic Modulators of Pain
- Phenotypic and High-throughput Assays for Screening
- Biologics as Next-generation Analgesics
- Challenges with in vitro to in vivo Translation
- In vivo Models of Pain: Inherent Limitations and Opportunities
- Validation and Use of Neuroimaging tools and Biomarkers
- Outsourcing CNS Drug Discovery: What and When to Outsource
Tentative Topics for Conference Short Courses include:
- Animal Models of Pain
- Role of Epigenetics in Pain: New Pathways and Targets for Modulation
- Use of Companion Diagnostics for Driving Precision Medicine in CNS Disorders
Scientists who wish to present their knowledge and expertise to their colleagues as a podium or poster presentation are asked to submit an abstract.
Click here to submit a speaking proposal. Remember to specify the conference that you are interested in and please provide your full contact information.
Visit www.worldpharmacongress.com to register for a very special early-bird discounted rate.
The deadline for submission is November 1, 2013.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For questions or suggestions about the meeting, contact:
Tanuja Koppal, Ph.D.
Cambridge Healthtech Institute
Phone: (+1) 973-525-4667
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431